2024
Incidence and risk factors of pain crisis after hematopoietic cell transplantation for sickle cell disease
Krishnamurti L, Liang J, He Z, Deng Y, Nallagatla V, Hamidi R, Flagg A, Shah N. Incidence and risk factors of pain crisis after hematopoietic cell transplantation for sickle cell disease. Blood Advances 2024, 8: 1908-1919. PMID: 38324722, PMCID: PMC11021890, DOI: 10.1182/bloodadvances.2023010749.Peer-Reviewed Original ResearchHematopoietic cell transplantationSickle cell diseaseVaso-occlusive episodesPainful crisesCell transplantationPost-HCTGraft failureBefore HCTEvent-free survivalOverall survivalPain syndromePatient agePatient-centered outcomesAlternative donorsIncreased riskCell diseaseRisk factorsNatural historyPatientsLogistic regressionPainTransplantationSurvivalAgeAGVHD
2022
Multimodal phenotyping and correlates of pain following hematopoietic cell transplant in children with sickle cell disease
Bakshi N, Astles R, Chou E, Hurreh A, Sil S, Sinha C, Sanders K, Peddineni M, Gillespie S, Keesari R, Krishnamurti L. Multimodal phenotyping and correlates of pain following hematopoietic cell transplant in children with sickle cell disease. Pediatric Blood & Cancer 2022, 70: e30046-e30046. PMID: 36322607, PMCID: PMC9820671, DOI: 10.1002/pbc.30046.Peer-Reviewed Original ResearchConceptsHematopoietic cell transplantPatient-reported outcomesSickle cell diseaseYear post-HCTPost-HCTExperimental pain sensitivitySickle cell anemiaCell transplantPain thresholdPain sensitivityCell diseaseCorrelates of painPressure pain thresholdHealth-related qualityCold pain thresholdAssessment of painPsychological factorsUnderstanding of painEffect sizePain assessmentObservational studySevere genotypePainCell anemiaOptional substudies
2021
Intraindividual pain variability and phenotypes of pain in sickle cell disease: a secondary analysis from the Pain in Sickle Cell Epidemiology Study
Bakshi N, Gillespie S, McClish D, McCracken C, Smith W, Krishnamurti L. Intraindividual pain variability and phenotypes of pain in sickle cell disease: a secondary analysis from the Pain in Sickle Cell Epidemiology Study. Pain 2021, 163: 1102-1113. PMID: 34538841, PMCID: PMC9100443, DOI: 10.1097/j.pain.0000000000002479.Peer-Reviewed Original ResearchConceptsSickle cell diseaseSickle Cell Epidemiology StudyOpioid useMean painPain variabilityPhysical functionPain intensityPain phenotypesPatient outcomesCell diseaseEpidemiology studiesHigher mean painLower mean painLow physical functionHealth-related qualityHealth care utilizationHigher physical functionProportion of daysSomatic symptom burdenSymptom burdenCare utilizationPainSecondary analysisSpearman rank correlationHigh temporal instabilityA pilot study of the acceptability, feasibility and safety of yoga for chronic pain in sickle cell disease
Bakshi N, Cooley A, Ross D, Hawkins L, Sullivan M, Astles R, Sinha C, Katoch D, Peddineni M, Gee B, Lane P, Krishnamurti L. A pilot study of the acceptability, feasibility and safety of yoga for chronic pain in sickle cell disease. Complementary Therapies In Medicine 2021, 59: 102722. PMID: 33892094, PMCID: PMC8284565, DOI: 10.1016/j.ctim.2021.102722.Peer-Reviewed Original ResearchConceptsProportion of participantsSafety of yogaChronic painSickle cell diseaseYoga sessionsYoga programED visitsMedian ageCell diseasePart ARetention of participantsFeasibility endpointsPain characteristicsPart BPain diaryAdolescent patientsYoga interventionClinical trialsPatient participantsSafety outcomesPainPilot studyMost participantsStudy assessmentYoga
2020
Prevalence and predictors of chronic pain intensity and disability among adults with sickle cell disease
Matthie N, Jenerette C, Gibson A, Paul S, Higgins M, Krishnamurti L. Prevalence and predictors of chronic pain intensity and disability among adults with sickle cell disease. Health Psychology Open 2020, 7: 2055102920917250. PMID: 32426150, PMCID: PMC7218472, DOI: 10.1177/2055102920917250.Peer-Reviewed Original ResearchChronic pain intensitySickle cell diseasePain intensityCell diseaseChronic painConsistent clinical assessmentPalliative care approachChronic pain impactMiddle-aged adultsPain impactPain catastrophizingClinical assessmentCare approachPsychosocial healthDisability prevalencePsychosocial predictorsYoung womenDiseaseMost participantsDisabilityPainAdultsCatastrophizingPrevalenceAge
2019
End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings
Farrell A, Panepinto J, Desai A, Kassim A, Lebensburger J, Walters M, Bauer D, Blaylark R, DiMichele D, Gladwin M, Green N, Hassell K, Kato G, Klings E, Kohn D, Krishnamurti L, Little J, Makani J, Malik P, McGann P, Minniti C, Morris C, Odame I, Oneal P, Setse R, Sharma P, Shenoy S. End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings. Blood Advances 2019, 3: 4002-4020. PMID: 31809537, PMCID: PMC6963248, DOI: 10.1182/bloodadvances.2019000883.Peer-Reviewed Original ResearchConceptsLow-resource settingsEnd pointClinical trial end pointsTrial end pointsPatient-reported outcomesSickle cell disease clinical trialsPanel of cliniciansSickle cell diseaseMeasurement of cureClinical trialsNovel therapiesCell diseaseConsensus recommendationsGlobal burdenUS FoodBiomarker panelDrug AdministrationAvailable evidenceAmerican SocietyCureRelevant findingsLiterature reviewPainPatientsTherapyManagement of Chronic Pain in Adults Living With Sickle Cell Disease in the Era of the Opioid Epidemic
Sinha C, Bakshi N, Ross D, Krishnamurti L. Management of Chronic Pain in Adults Living With Sickle Cell Disease in the Era of the Opioid Epidemic. JAMA Network Open 2019, 2: e194410. PMID: 31125105, PMCID: PMC6632133, DOI: 10.1001/jamanetworkopen.2019.4410.Peer-Reviewed Original ResearchConceptsSickle cell diseaseOpioid epidemicOpioid usePain managementChronic painAlternative therapiesCell diseaseAfrican American race/ethnicityDisease controlVaso-occlusive painPain medication useChronic pain managementSickle cell clinicCurrent opioid epidemicRace/ethnicityOpioid dosingOpioid dosageOpioid prescriptionsAdult patientsMedian ageMedication usePersistent painComprehensive careMAIN OUTCOMEPain
2018
A Qualitative Study of Chronic Pain and Self-Management in Adults with Sickle Cell Disease
Matthie N, Ross D, Sinha C, Khemani K, Bakshi N, Krishnamurti L. A Qualitative Study of Chronic Pain and Self-Management in Adults with Sickle Cell Disease. Journal Of The National Medical Association 2018, 111: 158-168. PMID: 30266214, PMCID: PMC6433553, DOI: 10.1016/j.jnma.2018.08.001.Peer-Reviewed Original ResearchConceptsSickle cell diseaseChronic pain managementChronic painChronic pain experiencePain managementCell diseasePain experienceChronic SCD painGreater QoL impairmentVaso-occlusive painYears of ageSelf-management strategiesSickle cell anemiaSubgroup of adultsSCD painAcute painPersistent painSubstantial morbidityHealthcare utilizationImpaired qualityQoL impairmentPainSCD managementCell anemiaQualitative studyAssociation of genetic variation in COMT gene with pain related to sickle cell disease in patients from the walk-PHaSST study
Zhang Y, Belfer I, Nouraie M, Zeng Q, Goel R, Chu Y, Krasiy I, Krishnamurti L. Association of genetic variation in COMT gene with pain related to sickle cell disease in patients from the walk-PHaSST study. Journal Of Pain Research 2018, 11: 537-543. PMID: 29559808, PMCID: PMC5856032, DOI: 10.2147/jpr.s149958.Peer-Reviewed Original ResearchVaso-occlusive pain episodesSickle cell diseasePain perceptionSCD patientsCell diseaseAfrican American SCD patientsVariability of painEmergency room visitsHealth care utilizationSelf-reported painPain episodesAcute painCare utilizationRoom visitsSS patientsFunctional variantsPainPatientsPsychological covariatesDisease biologyCOMT geneDiseaseRisk SNPsWomenCorresponding haplotypesQuantitative sensory testing is feasible and is well-tolerated in patients with sickle cell disease following a vaso-occlusive episode
Bakshi N, Lukombo I, Belfer I, Krishnamurti L. Quantitative sensory testing is feasible and is well-tolerated in patients with sickle cell disease following a vaso-occlusive episode. Journal Of Pain Research 2018, 11: 435-443. PMID: 29503580, PMCID: PMC5827673, DOI: 10.2147/jpr.s150066.Peer-Reviewed Original ResearchVaso-occlusive episodesQuantitative sensory testingSickle cell diseaseChronic painPain sensitivityCell diseaseSensory testingPainful vaso-occlusive episodesExperience chronic painFeasibility of recruitmentLarge prospective studiesEmergency room visitsExperimental pain sensitivityInherited blood disorderAltered painMedian agePain intensityPediatric patientsRoom visitsProspective studyInpatient hospitalizationSubset of individualsPainPatientsBlood disorders
2015
Development, Content Validity, and User Review of a Web-based Multidimensional Pain Diary for Adolescent and Young Adults With Sickle Cell Disease
Bakshi N, Stinson J, Ross D, Lukombo I, Mittal N, Joshi S, Belfer I, Krishnamurti L. Development, Content Validity, and User Review of a Web-based Multidimensional Pain Diary for Adolescent and Young Adults With Sickle Cell Disease. The Clinical Journal Of Pain 2015, 31: 580-590. PMID: 25565585, DOI: 10.1097/ajp.0000000000000195.Peer-Reviewed Original ResearchConceptsSickle cell diseasePain diaryHealth care utilizationElectronic pain diaryYoung adultsCare utilizationCell diseasePoor health-related qualityContent validityVaso-occlusive painDaily pain diarySeverity of painHealth-related qualityPain burdenModification of itemsPain experiencePainPatientsEnd-user reviewsElectronic diaryDiseaseAdultsAdolescentsPsychometric propertiesDiary
2011
Clinical trial implementation and recruitment: Lessons learned from the early closure of a randomized clinical trial
Peters-Lawrence M, Bell M, Hsu L, Osunkwo I, Seaman P, Blackwood M, Guillaume E, Bellevue R, Krishnamurti L, Smith W, Dampier C, Minniti C, Network F. Clinical trial implementation and recruitment: Lessons learned from the early closure of a randomized clinical trial. Contemporary Clinical Trials 2011, 33: 291-297. PMID: 22155024, PMCID: PMC3577351, DOI: 10.1016/j.cct.2011.11.018.Peer-Reviewed Original ResearchConceptsNew England Research InstituteClinical trialsRandomized clinical trialsFuture clinical trialsClinical trial implementationComplex dosing schedulesClinical Research NetworkPatient Controlled AnalgesiaProtocol acceptanceSCD clinicPain controlPain crisisAcute painDosing schedulesAcute interventionOutside physiciansUrgent careEligibility criteriaEnrollment periodPatient encountersEarly closurePainRecruitment barriersTrialsStaff availabilityHospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity
Machado R, Barst R, Yovetich N, Hassell K, Kato G, Gordeuk V, Gibbs J, Little J, Schraufnagel D, Krishnamurti L, Girgis R, Morris C, Rosenzweig E, Badesch D, Lanzkron S, Onyekwere O, Castro O, Sachdev V, Waclawiw M, Woolson R, Goldsmith J, Gladwin M. Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood 2011, 118: 855-864. PMID: 21527519, PMCID: PMC3148167, DOI: 10.1182/blood-2010-09-306167.Peer-Reviewed Original ResearchConceptsTricuspid regurgitation velocitySickle cell diseaseLower exercise capacityExercise capacityCell diseaseN-terminal pro-brain natriuretic peptideElevated tricuspid regurgitation velocityPro-brain natriuretic peptideSerious adverse eventsPulmonary arterial hypertensionSildenafil trialArterial hypertensionAdverse eventsWalk distanceDoppler echocardiographySCD patientsHospitalization ratesNatriuretic peptidePatientsSildenafilPredominant causePainHospitalizationTreatment effectsDisease